PLSE

NEUTRALTechnical

Pulse Biosciences, Inc

2026-09-03

Price

$54.71

+3.85%

This is the 2026-09-03 snapshot — the signals and analysis for PLSE as of this single trading day.

View full PLSE research hub →

Score3.2Watchlist

Signals4/8 DNA1/13 Act · 2/4 Risk

SentimentNEUTRALScore: 8

Volume1.3xvs 20d avg

Analysis

Pulse Biosciences (PLSE) is surging because the market is heavily rewarding its atrial fibrillation trial progress and recent insider buying, entirely shrugging off a recent Q2 earnings miss. This price action is a textbook example of Institutional Absorption, where strong technical signals like PERFECT_STACK and MARKET_LEADER confirm a High-Conviction Price Discovery phase. Furthermore, the RISK_ON (RATES) macro regime and exceptionally tight credit spreads provide the perfect liquidity backdrop for pre-profitable med-tech names, allowing investors to confidently bid up the forward-looking clinical pipeline.

Fired Signals

ALPHA MALEGOLDEN CROSSMARKET LEADERPERFECT STACKINSIDE OUTWEAK FINISHEXTENSION

Key Takeaways

Actionable Thesis: PLSE is exhibiting High-Conviction Price Discovery, making it a strong momentum long as institutional buyers absorb early fundamental weakness in favor of clinical potential.
Key Risk: With 76.3% annualized volatility and a negative P/E, the stock is highly duration-sensitive and vulnerable to any sudden shifts in the rates regime or clinical setbacks.
What to Watch: Monitor the immediate breakout level at current highs for continuation, while strictly managing downside risk against the $30.23 structural support.

← Back to 2026-09-03 View Full PLSE History →Yahoo Finance &nearr;